Success Stories: EB-2 NIW and EB1A Approved for Pharmaceutical Scientist
Client’s Testimonial:
“It is amazing news. I have no words to thank you. I want to thank all attorneys and any personnel involved in the filing. I am very impressed with how you make a case. With 309 citations, it was a nightmare to get EB1A. Thank you so much for your help, support, and quick service.”
On July 11th, 2025, and January 22nd, 2025, we received another EB-2 NIW (National Interest Waiver) and EB-1A (Alien of Extraordinary Ability) approvals for a Research Scientist in the Field of Pharmaceutical Science (Approval Notice).
General Field: Pharmaceutical Science and Pharmacology
Position at the Time of Case Filing: Post-Doctoral Research Scholar
Country of Origin: India
State of Residence at the Time of Filing: Iowa
Approval Notice Date: : July 11th, 2025 (NIW) and January 22nd, 2025 (EB1A)
Processing Time: 1 year, 6 months, 5 days (NIW) / 4 months, 19 days (EB1A) (Premium Processing Requested)
Case Summary:
We are pleased to share the success story of our client, a distinguished expert in pharmaceutical science and pharmacology, who has achieved both EB-2 NIW and EB1A (Extraordinary Ability) approvals with the legal guidance of the North America Immigration Law Group (NAILG).
Our client’s research plays a vital role in addressing the rising burden of stroke in the U.S. and globally. By uncovering new pathways for therapeutic intervention, his work directly supports the development of more precise and effective treatments for neurological conditions. These contributions not only advance scientific discovery but also promise long-term improvements in patient outcomes and public health.
To support his NIW and EB1A petitions, NAILG meticulously documented our client’s achievements, focusing on both the national importance of his research and the exceptional merit of his qualifications. Notably, our client’s EB1A petition initially received a Notice of Intent to Deny (NOID), but our team provided a comprehensive and persuasive response that successfully led to approval on January 22, 2025. This outcome underscores both the strength of our client’s case and NAILG’s experience in navigating complex adjudications.
NAILG’s petition demonstrated the significance of his record with the following supporting details:
- 18 peer-reviewed journal articles (4 first-authored), 1 book chapter, and 6 abstracts
- 309 citations on Google Scholar
- At least 80 peer reviews completed
Additionally, an expert testimonial submitted with the petition described his influence on the field:
“In summary, [client] is a highly influential and uniquely skilled figure in
pharmaceutical science and pharmacology. His research consistently improves medical research initiatives worldwide, empowering rapid and effective developments in drug discovery. Ensuring the continuation of [client]’s work is thus deeply important to the nation.”
Our client’s EB-2 NIW and EB-1A approval stands as a testament to both the value of his scientific contributions and the strength of NAILG’s petition strategy. We are proud to have guided him through this process and look forward to the continued impact of his research on neurological health and therapeutic innovation.

